Related Experiment Video
Updated: Aug 8, 2026
05:04
Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
Published on: February 2, 2024
Pediatric Ataxia and Emerging Treatments
Heather Brown1, Kristin Barañano2
1Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pediatric Neurology
|August 6, 2026
Summary
Pediatric ataxia presents diversely. While new treatments are emerging, survivorship remains unchanged, emphasizing multidisciplinary care and palliative support for managing complications in children with ataxia.
Area of Science:
- Neurology
- Pediatrics
- Genetics
Background:
- Pediatric ataxia encompasses diverse clinical presentations, including acute, subacute, episodic, and chronic/progressive forms.
- Understanding the diagnostic landscape is crucial for effective management.
Purpose of the Study:
- To review diagnostic strategies for chronic and progressive pediatric ataxias.
- To provide an overview of emerging and pipeline disease-modifying therapies.
- To highlight current approaches to survivorship and complication management.
Main Methods:
- Literature review of diagnostic approaches for pediatric ataxia.
- Review of current and emerging treatment strategies.
- Analysis of survivorship data and management recommendations.
Main Results:
- Diagnostic strategies for chronic/progressive pediatric ataxias are established.
- Emerging treatments and disease-modifying therapies are under development.
- Survivorship in pediatric ataxia has not significantly improved.
Conclusions:
- Focus remains on managing long-term complications in pediatric ataxia.
- A multidisciplinary team approach is essential for optimal care.
- Palliative care plays a vital role in supporting patients and families.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...